Hikma Pharmaceuticals

Pharmaceuticals

HIK.L

GBX 1,738 2

Share price

$ 4.9 bn

Market Cap

$ 5.5 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.79x the weighted average for S&P 500

FY2020

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Hikma Pharmaceuticals reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 124 Kt (-0.44 /-0.4% y-o-y). Also positively, carbon intensity decreased to 53 t (-3.5 /-6.2% y-o-y).

Hikma Pharmaceuticals reported Scope 3 emissions for the the twelve months ending31 December 2020 at 0.8

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	124	41	83		2,341	53
2019Q4	125	39	86		2,207	57
2018Q4	128	38	90	0.8	2,070	62
2017Q4	129	37	92		1,936	67

Hikma Pharmaceuticals

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Hikma Pharmaceuticals's carbon footprint

Company environmental metrics